TABLE 1 | Recent patent applications related to FAAH modulators
From the following article:
Nature Reviews Drug Discovery 7, 380-381 (May 2008)
doi:10.1038/nrd2586
| Patent number(s) | Assignee(s) | Subject |
|---|---|---|
| US 20070088073
WO 2007047839 | Allergen | These describe new 1H-indol-5-ol derivatives that bind to FAAH to enhance endocannabinoid levels, and also act as TRPV1 antagonists; useful for treating neuropathic pain with high efficacy against inflammatory hyperalgesia. |
| EP 1849773 | Astellas Pharma | Describes a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate ester derivative or its salt that is a potent FAAH inhibitor; useful for treating urinary incontinence, overactive bladder or pain. |
| WO 2007140005 | Janssen–Cilag | Describes new oxazolyl piperidine compounds that are potent FAAH inhibitors; useful (in combination with an analgesic) for treating anxiety, pain, sleep disorders, eating disorders, inflammation and multiple sclerosis. |
| WO 2007061862 | Janssen–Cilag | Describes new substituted 2-keto-oxazole compounds that are FAAH modulators; useful for treating pain, inflammation, multiple sclerosis and stroke. |
| EP 1836179 | Janssen–Cilag | Claims the use of piperazinyl and piperidinyl ureas as potent modulators of FAAH, which, when combined with another active compound, increases efficacy, and decreases side effects or required dose. |
| US 20070155707
WO 2008020866 | Kadmus Pharmaceuticals and Organon | These describe new substituted carbamic acid phenyl ester compounds that are irreversible FAAH inhibitors that do not substantially cross the blood–brain barrier. |
| US 20070155747
WO 2007079180 WO 2008021625 WO 2008022976 | Kadmus Pharmaceuticals and Organon | These describe new carbamate compounds that are FAAH inhibitors; useful for treating eating disorders, cardiovascular diseases, metabolic diseases, osteoporosis, ocular conditions, pulmonary conditions and gastrointestinal diseases. |
| JP 2007524707
JP 2007524704 EP 1720848 | Sanofi–Aventis | These describe new C-alkyl-piperidine-1-carboxylate derivatives and 1-alkyl-(homo)piperazine-4-carboxylate ester derivatives that are FAAH inhibitors; useful for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic diseases. |
| JP 2007524705
JP 2007522111 JP 2007524706 | Sanofi–Aventis | These describe new carbamoylalkyl alkylcarbamate ester derivatives, new O-aminocarbonylmethyl carbamate derivatives, new 1-alkyl-piperidine-4-carbamate derivatives and analogues that are FAAH inhibitors; useful for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic diseases. |
| JP 2007519628
EP 1701946 | Sanofi–Aventis | These describe new 1-carboxy-piperazine or -homopiperazine derivatives that are FAAH inhibitors; useful for the treatment and prevention of pain and cancer. |
| WO 2007098142
US 20070203156 | Scripps Research Institute | These describe new oxazole-ketone derivatives that are FAAH modulators; useful (in combination with an opioid or NSAID) for treating anxiety, pain, sleep disorders, eating disorders and inflammation. |
| EP 1812427 | Scripps Research Institute | Describes new oxadiazole ketone compounds that are potent FAAH modulators; useful for treating anxiety, pain, sleep disorders, eating disorders and inflammation. |
| EP 1813606 | Takeda | Describes a new amide compound having high FAAH inhibitory activity; useful as a brain and neuroprotective agent, and therapeutic agent for cerebrovascular diseases, head trauma or spinal injury. |
| FAAH, fatty acid amide hydrolase; NSAID, non-steroidal anti-inflammatory drug; TRPV1, transient receptor potential, vanilloid subtype 1 receptor. | ||
Download file
If the slide opens in your browser, select "File > Save As" to save it.
